Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 4/20 | 0.40 |
| ▸ | MME | P08473 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | PEPD | P12955 | 2/20 | 0.36 |
| ▸ | XPNPEP1 | Q9NQW7 | 1/20 | 0.36 |
| ▸ | CASP1 | P29466 | 4/20 | 0.35 |
| ▸ | FKBP1A | P62942 | 2/20 | 0.35 |
| ▸ | LCK | P06239 | 2/20 | 0.34 |
| ▸ | LTA4H | P09960 | 2/20 | 0.34 |
| ▸ | IL1B | P01584 | 1/20 | 0.34 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
| ▸ | MMP2 | P08253 | 1/20 | 0.33 |
| ▸ | ANPEP | P15144 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL949749 | 0.86 | ACE (0.40) | ACEMMECASP1LCK | |
| SCHEMBL644711 | 0.86 | ACE (0.40) | ACEMMECASP1LCK | |
| SCHEMBL14078890 | 0.85 | ACE (0.42) | ACEMMECASP1LCKIL1B | |
| SCHEMBL10663842 | 0.84 | ACE (0.40) | ACEMMEPOLBPEPDXPNPEP1 | |
| SCHEMBL645674 | 0.83 | ACE (0.56) | ACEMMECASP1IL1B | |
| SCHEMBL6627295 | 0.83 | ACE (0.43) | ACEMMECASP1LCKIL1B | |
| SCHEMBL7088512 | 0.83 | ACE (0.56) | ACEMMECASP1IL1B | |
| SCHEMBL7339985 | 0.83 | ACE (0.56) | ACEMMECASP1IL1B | |
| SCHEMBL7088511 | 0.83 | ACE (0.56) | ACEMMECASP1IL1B | |
| Water SCHEMBL10565338 | 0.82 | ACE (0.54) | ACEMMECASP1IL1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2848696-A1 | Caspase-1 imaging probes | Sanofi-Aventis Deutschland GmbH (DE) | 2015-03-18 | — | — | EP | disclosed |
| US-20110059018-A1 | COVALENTLY BINDING IMAGING PROBES | SANOFI-AVENTIS (FR) | 2011-03-10 | — | — | US | disclosed |
| EP-2262783-A2 | COVALENTLY BINDING IMAGING PROBES | Sanofi-Aventis (FR) | 2010-12-22 | — | — | EP | disclosed |
| WO-2009103432-A2 | COVALENTLY BINDING IMAGING PROBES | SANOFI-AVENTIS (FR) | 2009-08-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110059018-A1 | COVALENTLY BINDING IMAGING PROBES | CTSV, CTSL, CTSE | ACE 684/4885MME 204/4885POLB 1749/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.